Kort Nieuws
-
22 mei 2022Recidiverende IPTV handelaar raakt cryptovaluta kwijt na beslag door BREIN
-
22 mei 2022Board of Appeal agrees that the description amendment requirement lacks legal basis (T 1444/20)
-
22 mei 2022Gilstrap Won't Rearrange Patent Trials To Let Google Go First
-
22 mei 20229th Circ. Says Delta-8 Vapes Are Federally Lawful In TM Case
-
22 mei 2022Travel Reward App Can't Escape American Airlines' TM Suit
-
18 mei 2022Jort Kelder verliest zaak tegen Google en Twitter
-
18 mei 2022UK Intellectual Property Office publishes strategy and priorities
-
18 mei 2022[Guest Post] The African Group’s Proposal on a Work Program on Limitations and Exceptions Moves Forward in WIPO’s Committee on Copyright
-
18 mei 2022PTAB Cases Dip As Board Leans On Discretionary Denials
-
18 mei 2022Even With Pandemic, Patent Suit Filings Held Steady In 2021
-
16 mei 2022Turning back the clock for a restoration request (J 14/21)
-
16 mei 2022Change is afoot in the music industry as French record labels and performers agree landmark deal for streaming remuneration
-
15 mei 2022A decade later, and the Zara trade mark saga continues
-
12 mei 2022NVJ bereidt klacht voor over verbod Sputnik en RT
-
11 mei 2022Logo Meta onder vuur
-
11 mei 2022What does the CJEU judgment in the Polish challenge to Article 17 (C-401/19) mean for the transposition and application of that provision?
-
11 mei 2022Copyright case: Canada Hockey, L.L.C. v. Marquardt, USA
-
11 mei 2022Jury Clears Loofah Maker Of Infringing Patent
-
11 mei 2022Nike Adds Fuel To StockX TM Fight Over Sneaker NFTs
-
11 mei 2022How Russia's Parallel Import Order May Affect Companies' IP
- KORT NIEUWS
-
31 maartBreed vervolg handhaving tegen illegaal vinyl
-
31 maartDean Lewis verliest rechtszaak tegen Nederlandse vrouw
-
30 maartAG Emiliou advises CJEU to rule that OCSSPs' authorization under Article 17 of the DSM Directive extends to acts of reproduction
-
30 maartMAN v Rolls-Royce – How not to advertise your mark
-
30 maartPatenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell)























































































